Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)

Patricia Fellows, Jeffrey Adamovicz, Justin Hartings, Robert Sherwood, William Mega, Trevor Brasel, Ed Barr, Lou Holland, Winston Lin, Amanda Rom, William Blackwelder, Jessica Price, Stephen Morris, Doris Snow, Mary Kate Hart

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Passive transfer models were developed to evaluate the ability of antibodies generated in cynomolgus macaques and humans vaccinated with a recombinant plague vaccine (rF1V) to protect naïve Swiss Webster mice against pneumonic plague. Development of the passive transfer model is intended to support clinical and nonclinical development of the rF1V vaccine. To evaluate protection, unfractionated serum collected from rF1V vaccinated cynomolgus macaques and human volunteers with known antibody titers to rF1, rV and rF1V was transferred into naïve Swiss Webster mice via the intraperitoneal route. Results of these studies demonstrated that passive immunization protected mice from challenge or extended mean survival time and that the passive transfer assay can be used to evaluate the functional role of antibodies induced by rF1V vaccination in protection against aerosol exposure.

Original languageEnglish (US)
Pages (from-to)7748-7756
Number of pages9
JournalVaccine
Volume28
Issue number49
DOIs
StatePublished - Nov 16 2010
Externally publishedYes

Fingerprint

Plague Vaccine
Synthetic Vaccines
plague
Macaca fascicularis
Macaca
vaccines
antibodies
Antibodies
mice
Serum
Passive Immunization
Plague
vaccine development
aerosols
Aerosols
volunteers
Volunteers
immunization
Vaccination
Vaccines

Keywords

  • Passive transfer
  • Pneumonic plague
  • RF1V vaccine
  • Yersinia pestis

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Fellows, P., Adamovicz, J., Hartings, J., Sherwood, R., Mega, W., Brasel, T., ... Hart, M. K. (2010). Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V). Vaccine, 28(49), 7748-7756. https://doi.org/10.1016/j.vaccine.2010.09.062

Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V). / Fellows, Patricia; Adamovicz, Jeffrey; Hartings, Justin; Sherwood, Robert; Mega, William; Brasel, Trevor; Barr, Ed; Holland, Lou; Lin, Winston; Rom, Amanda; Blackwelder, William; Price, Jessica; Morris, Stephen; Snow, Doris; Hart, Mary Kate.

In: Vaccine, Vol. 28, No. 49, 16.11.2010, p. 7748-7756.

Research output: Contribution to journalArticle

Fellows, P, Adamovicz, J, Hartings, J, Sherwood, R, Mega, W, Brasel, T, Barr, E, Holland, L, Lin, W, Rom, A, Blackwelder, W, Price, J, Morris, S, Snow, D & Hart, MK 2010, 'Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)', Vaccine, vol. 28, no. 49, pp. 7748-7756. https://doi.org/10.1016/j.vaccine.2010.09.062
Fellows, Patricia ; Adamovicz, Jeffrey ; Hartings, Justin ; Sherwood, Robert ; Mega, William ; Brasel, Trevor ; Barr, Ed ; Holland, Lou ; Lin, Winston ; Rom, Amanda ; Blackwelder, William ; Price, Jessica ; Morris, Stephen ; Snow, Doris ; Hart, Mary Kate. / Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V). In: Vaccine. 2010 ; Vol. 28, No. 49. pp. 7748-7756.
@article{a5a522512b6b464195f84ec0180616a4,
title = "Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)",
abstract = "Passive transfer models were developed to evaluate the ability of antibodies generated in cynomolgus macaques and humans vaccinated with a recombinant plague vaccine (rF1V) to protect na{\"i}ve Swiss Webster mice against pneumonic plague. Development of the passive transfer model is intended to support clinical and nonclinical development of the rF1V vaccine. To evaluate protection, unfractionated serum collected from rF1V vaccinated cynomolgus macaques and human volunteers with known antibody titers to rF1, rV and rF1V was transferred into na{\"i}ve Swiss Webster mice via the intraperitoneal route. Results of these studies demonstrated that passive immunization protected mice from challenge or extended mean survival time and that the passive transfer assay can be used to evaluate the functional role of antibodies induced by rF1V vaccination in protection against aerosol exposure.",
keywords = "Passive transfer, Pneumonic plague, RF1V vaccine, Yersinia pestis",
author = "Patricia Fellows and Jeffrey Adamovicz and Justin Hartings and Robert Sherwood and William Mega and Trevor Brasel and Ed Barr and Lou Holland and Winston Lin and Amanda Rom and William Blackwelder and Jessica Price and Stephen Morris and Doris Snow and Hart, {Mary Kate}",
year = "2010",
month = "11",
day = "16",
doi = "10.1016/j.vaccine.2010.09.062",
language = "English (US)",
volume = "28",
pages = "7748--7756",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "49",

}

TY - JOUR

T1 - Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)

AU - Fellows, Patricia

AU - Adamovicz, Jeffrey

AU - Hartings, Justin

AU - Sherwood, Robert

AU - Mega, William

AU - Brasel, Trevor

AU - Barr, Ed

AU - Holland, Lou

AU - Lin, Winston

AU - Rom, Amanda

AU - Blackwelder, William

AU - Price, Jessica

AU - Morris, Stephen

AU - Snow, Doris

AU - Hart, Mary Kate

PY - 2010/11/16

Y1 - 2010/11/16

N2 - Passive transfer models were developed to evaluate the ability of antibodies generated in cynomolgus macaques and humans vaccinated with a recombinant plague vaccine (rF1V) to protect naïve Swiss Webster mice against pneumonic plague. Development of the passive transfer model is intended to support clinical and nonclinical development of the rF1V vaccine. To evaluate protection, unfractionated serum collected from rF1V vaccinated cynomolgus macaques and human volunteers with known antibody titers to rF1, rV and rF1V was transferred into naïve Swiss Webster mice via the intraperitoneal route. Results of these studies demonstrated that passive immunization protected mice from challenge or extended mean survival time and that the passive transfer assay can be used to evaluate the functional role of antibodies induced by rF1V vaccination in protection against aerosol exposure.

AB - Passive transfer models were developed to evaluate the ability of antibodies generated in cynomolgus macaques and humans vaccinated with a recombinant plague vaccine (rF1V) to protect naïve Swiss Webster mice against pneumonic plague. Development of the passive transfer model is intended to support clinical and nonclinical development of the rF1V vaccine. To evaluate protection, unfractionated serum collected from rF1V vaccinated cynomolgus macaques and human volunteers with known antibody titers to rF1, rV and rF1V was transferred into naïve Swiss Webster mice via the intraperitoneal route. Results of these studies demonstrated that passive immunization protected mice from challenge or extended mean survival time and that the passive transfer assay can be used to evaluate the functional role of antibodies induced by rF1V vaccination in protection against aerosol exposure.

KW - Passive transfer

KW - Pneumonic plague

KW - RF1V vaccine

KW - Yersinia pestis

UR - http://www.scopus.com/inward/record.url?scp=78349312669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349312669&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.09.062

DO - 10.1016/j.vaccine.2010.09.062

M3 - Article

C2 - 20920572

AN - SCOPUS:78349312669

VL - 28

SP - 7748

EP - 7756

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 49

ER -